Growth Entirely Driven by New Products, Says Roche CEO

The transcript covers a discussion on the strong sales performance driven by new products, particularly Akribos, and addresses investor concerns about biosimilar competition. It highlights the positive feedback for Hemlibra and strategies for the US market, including drug pricing transparency. The growth in the China market and the impact of trade wars are also discussed. Finally, the transcript touches on stock performance and future growth prospects, emphasizing the strong demand for new medicines and a robust pipeline.

What is the company's outlook on the US market for breakthrough medicines?

How is the healthcare system in China evolving, and what does it mean for the company's products?

What strategies does the company have in place to improve stock performance?